Coagulation-Targeted TGF-β Signaling Pathway Inhibitor Nanomedicine for Inhibiting the Growth and Lung Metastasis of Breast Cancer
Nano Letters · 08.01.2025 · 25 (1) · 504-513
DOI: 10.1021/acs.nanolett.4c05355 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano Letters, online erschienen am 16.12.2024. Verfasst von Yajun Xu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China. Hauptthemen laut MEDLINE: Transforming Growth Factor beta, Lung Neoplasms, Breast Neoplasms, Signal Transduction. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Key Technologies Research and Development Program, National Natural Science Foundation of China.
Abstract (Originalsprache)
The transforming growth factor β (TGF-β) signaling pathway exerts a dual role in oncogenesis, acting as a suppressor in healthy and early stage neoplastic tissues while promoting malignancy and metastasis in advanced cancers. Tumor hemorrhage further exacerbates TGF-β-mediated metastasis by up-regulating its expression. Here, a coagulation-targeting peptide (A15)-decorated TGF-β inhibitor nanomedicine (A15-LY-NPs) was developed. The tumor colonization assays showed that the nanomedicine reduced 4T1-luc cell colonization in normal tissues. When combined with a vascular disrupting agent, A15-LY-NPs demonstrated three times greater drug accumulation in the tumor at 24 h compared to the control and showed a 93.7% tumor suppression rate in 4T1 tumors initiated at ∼500 mm3, significantly attenuating metastatic spread to the lungs and liver. This study presents an innovative approach for the precise and efficient delivery of TGF-β inhibitors to tumors, offering the potential to augment the efficacy of cancer therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China.
- School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei 230026, China.
- Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun 130033, Jilin, China.
- Department of Breast Surgery, The Second Hospital of Jilin University, Changchun 130041, China.
- Department of Chemistry and Biochemistry, The University of Kitakyushu, 1-1 Hibikino, Kitakyushu 808-0135, Japan.
ORCID-Profile: Yajun Xu, Kazuo Sakurai, Zhaohui Tang, Xuesi Chen
Förderung
- Key Technologies Research and Development Program
- National Natural Science Foundation of China
Zitieren
APA
Xu, Y., Lv, J., Liu, Y., Du, J., Luo, C., Wang, Y., Liu, L., Sakurai, K., Tang, Z., & Chen, X. (2025). Coagulation-Targeted TGF-β Signaling Pathway Inhibitor Nanomedicine for Inhibiting the Growth and Lung Metastasis of Breast Cancer. Nano Letters, 25(1), 504-513. https://doi.org/10.1021/acs.nanolett.4c05355
Vancouver
Xu Y, Lv J, Liu Y, Du J, Luo C, Wang Y, et al. Coagulation-Targeted TGF-β Signaling Pathway Inhibitor Nanomedicine for Inhibiting the Growth and Lung Metastasis of Breast Cancer. Nano Letters. 2025;25(1):504-513. doi:10.1021/acs.nanolett.4c05355
BibTeX
@article{Xu2025,
author = {Xu, Yajun and Lv, Jianlin and Liu, Ya and Du, Jincheng and Luo, Chuwen and Wang, Ying and Liu, Linlin and Sakurai, Kazuo and Tang, Zhaohui and Chen, Xuesi},
title = {Coagulation-Targeted TGF-β Signaling Pathway Inhibitor Nanomedicine for Inhibiting the Growth and Lung Metastasis of Breast Cancer},
journal = {Nano Letters},
year = {2025},
volume = {25},
number = {1},
pages = {504--513},
doi = {10.1021/acs.nanolett.4c05355}
}
EUVIMED